The text discusses the use of oral 5-FU derivatives in adjuvant treatment for non-metastatic colon cancer, specifically the effectiveness of capecitabine compared to other treatment options. It emphasizes the importance of considering comorbidities and life expectancy when deciding on a treatment plan, and highlights the benefits of capecitabine in terms of survival rates and reduced side effects. Studies have shown that capecitabine is as effective as other treatments such as FUFOL and FOLFOX, with some studies showing superior outcomes for CAPOX in terms of disease-free survival and overall survival.